ImmuPharma secures £50m to develop ex-Cephalon asset
ImmuPharma has secured a £50 million, five-year equity financing facility to fund its late stage lupus treatment. This will allow the company to complete Phase III development of Lupuzor.
ImmuPharma has secured a £50 million, five-year equity financing facility to fund its late stage lupus treatment. This will allow the company to complete Phase III development of Lupuzor.